y, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Guaifenesin; Potassium Guaiacolsulfonate: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Guaifenesin; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Promethazine: (Major) Avoid coadministration of ribociclib with promethazine due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. Concomitant use may increase the risk for QT prolongation. (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Dextromethorphan; Quinidine: (Major) Avoid coadministration of ribociclib with quinidine due to an increased risk for QT prolongation and torsade de pointes (TdP). Systemic exposure of quinidine may be increased resulting in an increase in quinidine-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Quinidine has also been associated with QT prolongation and torsade de pointes (TdP). Concomitant use may increase the risk for QT prolongation. Ribociclib is also a moderate CYP3A4 inhibitor and quinidine is a CYP3A4 substrate with a narrow therapeutic window. (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Diazepam: (Moderate) Use caution if coadministration of ribociclib with diazepam is necessary, as the systemic exposure of diazepam may be increased resulting in increase in treatment-related adverse reactions; adjust the dose of diazepam if necessary. Ribociclib is a CYP3A4 inhibitor in vitro at clinically relevant concentrations. At low concentrations, diazepam is primarily metabolized by CYP2C19; however, CYP3A4 is also involved at higher concentrations.
Diclofenac: (Moderate) Use caution if coadministration of ribociclib with diclofenac is necessary, as the systemic exposure of diclofenac may be increased resulting in an increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and diclofenac is a CYP3A4 substrate.
Diclofenac; Misoprostol: (Moderate) Use caution if coadministration of ribociclib with diclofenac is necessary, as the systemic exposure of |
